Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Ministry of Health and Labour Welfare (MHLW-Japan), have issued a Good Manufacturing Practice (GMP) certificate for its non-sterile manufacturing site located at Dewas (India). The MHLW approval has been granted for a period of five years and will cover all products that are currently manufactured at this site and that will be filed in the future for Japan.

Earlier in January 2009, Ranbaxy received approval for two products that were filed from its Batamandi and Paonta Sahib (Ganguwala) manufacturing facilities at Paonta Sahib (India). These were subsequent to on-site inspections conducted in October 2008 by the Pharmaceutical and Medical Devices Agency (PMDA) Japan.

In March 2009, the Medicines and Healthcare products Regulatory Agency (MHRA) of UK, and the Therapeutic Goods Administration (TGA), Department of Health and Ageing of the Australian Government, had issued Good Manufacturing Practice (GMP) certificates for its manufacturing site at Paonta Sahib (India).

Ranbaxy remains committed to providing high quality generic medicines at affordable prices to its customers and patients in Japan, and the entire global marketplace.